Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering
Rani Therapeutics (NASDAQ: RANI), a clinical-stage biotherapeutics company, has announced a $3.0 million registered direct offering of its Class A common stock and pre-funded warrants. The company will sell 4,354,000 shares at $0.40 per share and pre-funded warrants for 3,146,000 shares at $0.3999 to a single institutional investor.
The offering, expected to close around July 16, 2025, is being conducted through Maxim Group LLC as the sole placement agent. The pre-funded warrants will have an exercise price of $0.0001 per share. The offering is made pursuant to an effective shelf registration statement, with proceeds subject to placement agent fees and offering expenses.
Rani Therapeutics (NASDAQ: RANI), un'azienda bioterapeutica in fase clinica, ha annunciato un offerta diretta registrata da 3,0 milioni di dollari delle sue azioni ordinarie di Classe A e warrant pre-finanziati. La società venderà 4.354.000 azioni a 0,40 dollari per azione e warrant pre-finanziati per 3.146.000 azioni a 0,3999 dollari a un singolo investitore istituzionale.
L'offerta, che si prevede venga chiusa intorno al 16 luglio 2025, è gestita da Maxim Group LLC come unico agente di collocamento. I warrant pre-finanziati avranno un prezzo di esercizio di 0,0001 dollari per azione. L'offerta è effettuata ai sensi di una dichiarazione di registrazione a scaffale efficace, con i proventi soggetti a commissioni dell'agente di collocamento e spese dell'offerta.
Rani Therapeutics (NASDAQ: RANI), una empresa biofarmacéutica en etapa clínica, ha anunciado una oferta directa registrada de 3,0 millones de dólares de sus acciones ordinarias Clase A y warrants prefinanciados. La compañía venderá 4,354,000 acciones a 0,40 dólares por acción y warrants prefinanciados para 3,146,000 acciones a 0,3999 dólares a un único inversor institucional.
La oferta, que se espera cierre alrededor del 16 de julio de 2025, se realiza a través de Maxim Group LLC como agente único de colocación. Los warrants prefinanciados tendrán un precio de ejercicio de 0,0001 dólares por acción. La oferta se realiza conforme a una declaración de registro en estantería efectiva, con los ingresos sujetos a comisiones del agente colocador y gastos de la oferta.
Rani Therapeutics (NASDAQ: RANI)는 임상 단계의 생물치료제 회사로서, 3백만 달러 규모의 등록 직접 공모를 발표했습니다. 이번 공모를 통해 회사는 주당 0.40달러에 4,354,000주와 주당 0.3999달러에 3,146,000주의 선납 워런트를 단일 기관 투자자에게 판매할 예정입니다.
이번 공모는 2025년 7월 16일경 마감될 예정이며, 단독 배정 대행사인 Maxim Group LLC를 통해 진행됩니다. 선납 워런트의 행사가격은
Rani Therapeutics (NASDAQ : RANI), une société biothérapeutique en phase clinique, a annoncé une offre directe enregistrée de 3,0 millions de dollars de ses actions ordinaires de Classe A et de ses bons de souscription préfinancés. La société vendra 4 354 000 actions à 0,40 dollar par action ainsi que des bons de souscription préfinancés pour 3 146 000 actions à 0,3999 dollar à un seul investisseur institutionnel.
L’offre, dont la clôture est prévue aux alentours du 16 juillet 2025, est réalisée par l’intermédiaire de Maxim Group LLC en tant qu’agent unique de placement. Les bons de souscription préfinancés auront un prix d’exercice de 0,0001 dollar par action. L’offre est effectuée en vertu d’un prospectus d’enregistrement en vigueur, les produits étant soumis aux frais d’agent de placement et aux dépenses liées à l’offre.
Rani Therapeutics (NASDAQ: RANI), ein biotherapeutisches Unternehmen in der klinischen Phase, hat ein registriertes Direktangebot über 3,0 Millionen US-Dollar seiner Stammaktien der Klasse A und vorfinanzierter Warrants angekündigt. Das Unternehmen wird 4.354.000 Aktien zu je 0,40 US-Dollar sowie vorfinanzierte Warrants für 3.146.000 Aktien zu 0,3999 US-Dollar an einen einzelnen institutionellen Investor verkaufen.
Das Angebot, dessen Abschluss für etwa 16. Juli 2025 erwartet wird, wird über Maxim Group LLC als alleinigen Platzierungsagenten durchgeführt. Die vorfinanzierten Warrants haben einen Ausübungspreis von 0,0001 US-Dollar pro Aktie. Das Angebot erfolgt gemäß einer wirksamen Shelf-Registrierungserklärung, wobei der Erlös um Platzierungsgebühren und Angebotkosten bereinigt wird.
- Secured immediate funding of $3.0 million through registered direct offering
- Single institutional investor commitment shows continued interest in the company
- Significant dilution to existing shareholders with issuance of 7.5 million new shares/warrants
- Low offering price of $0.40 per share suggests weak market position
- Small offering size of $3.0M indicates limited funding secured
Insights
Rani's $3M micro-financing at $0.40/share indicates severe financial distress with 91% share price erosion from IPO levels.
Rani Therapeutics'
This micro-financing with a single institutional investor rather than a broader offering suggests limited market interest and restricted financing options. The
This financing appears to be a stopgap measure rather than a strategic capital raise, potentially forcing the company to seek additional dilutive financings or strategic alternatives in the near term. The use of a shelf registration suggests opportunistic timing to secure even minimal funding. For context, when clinical-stage biotechs resort to such small raises at deep discounts, it often signals diminishing confidence in near-term catalysts that could improve financing terms.
SAN JOSE, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 4,354,000 shares of Rani Therapeutics’ Class A common stock at a purchase price of
Maxim Group LLC is acting as the sole placement agent for the offering.
The offering is expected to close on or about July 16, 2025, subject to satisfaction of customary closing conditions. The gross proceeds to Rani Therapeutics from this offering are expected to be approximately
The securities in the registered direct offering are being offered and sold by Rani pursuant to a "shelf" registration statement on Form S-3 (File No. 333-266444) which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on August 10, 2022. The offering of the securities is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the registered direct offering will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
media@ranitherapeutics.com
FAQ
What is the size and price of RANI's July 2025 registered direct offering?
When will RANI's registered direct offering close?
Who is the placement agent for RANI's offering?
How many shares and warrants are being offered in RANI's July 2025 offering?
What is the exercise price of RANI's pre-funded warrants?
